W8MD Diet | COVID-19 portal | Vitamin D | Vaccine | Keto

WikiMD is the world's largest medical encyclopedia with
13,351 pages, 4,229,031 edits & 44,076,700 views.

Free unbiased diet, health and wellness info!


From WikiMD's free health, diet & wellness encyclopedia
Jump to navigation Jump to search

Information about Trifluridine/Tipracil

Trifluridine/tipiracil is the combination of an antineoplastic pyrimidine analogue (trifluridine) with an inhibitor of its metabolism (tipiracil) that is used in the therapy of refractory, metastatic colorectal cancer. 

Liver toxicity

Trifluridine/tipiracil is associated with a low rate of transient serum enzyme elevations during therapy, but has not been implicated in cases of clinically apparent acute liver injury with jaundice. 

Mechanism of action of Trifluridine/Tipracil

Trifluridine (trye flure' i deen)/tipiracil (tye pir’ a sil) combines an antineoplastic pyrimidine analogue (2-deoxy-5-trifluoromethyl uridine) with a thymidine phosphorylase inhibitor that blocks its rapid metabolism, thus increasing the bioavailability of trifluridine.  Trifluridine is absorbed orally and converted intracellularly to a triphosphate which becomes incorporated into DNA causing inhibition of DNA synthesis, a decrease in cellular growth and proliferation and triggering apoptosis.  Trifluridine triphosphate is metabolized by thymidine phosphorylase which is inhibited by tipiracil, thus providing a longer half-life and increased intracellular concentrations of active phosphorylated trifluridine.  Trifluridine/tipiracil was shown to have potent activity in vitro in cellular and in vivo in animal models of colon cancer.  In clinical trials, this combination led to prolongation of progression-free as well as overall survival in patients with previously treated, refractory metastatic colorectal cancer

FDA approval information for Trifluridine/Tipracil

Trifluridine/tipiracil was approved for use in the United States in 2015 and is available in tablets of 15 mg/14 mg and 20 mg/19 mg under the commercial name Lonsurf. 

Clinical use of Trifluridine/Tipracil

Current indications are for refractory, metastatic colorectal cancer after previous treatment with other agents.  The recommended dose regimen is 35 mg/m2(based upon the trifluridine component) orally twice daily on days 1 through 5 and days 8 through 12 of each 28-day cycle. 

Side effects of Trifluridine/Tipracil

Common side effects include bone marrow suppression, weakness, fatigue, nausea, anorexia, diarrhea, abdominal pain and fever.  Less common, but potentially severe adverse events include severe myelosuppression, febrile neutropenia, infections, sepsis and embryo-fetal toxicity.

Alphabetic list of antineoplastic agents - 0-9 - A1 - A2 - A3 - A4 - A5 -A6 - B - C - D - E - F - G - H - I - JK - L - M - NO - PQ - R - S - T - UVW - XYZ


Cost and Coupons - Trifluridine/Tipracil

Reviews for Trifluridine/Tipracil

Learn more about Trifluridine/Tipracil

Latest research - Trifluridine/Tipracil

Clinical trials

External links

Medicine icon
Medicine icon

This WikiMD article Trifluridine/Tipracil is a stub. If you are familiar with the topic Trifluridine/Tipracil, you can help us. Paid editors welcome!


Trifluridine/Tipracil is part of WikiMD's free ^articles!

^Trifluridine/Tipracil (article) is provided for informational purposes only. No expressed or implied warranties as to the validity of content.
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP. Tele medicine available